IDO1 and major depressive disorder: While it is unclear if a similar upregulation is present in SB, a polymorphism in the promoter region of the IDO1 gene is associated with higher risk of developing MDD symptoms in individuals receiving IFN therapies (Smith et al., 2012), suggesting that IDO1 plays a significant role in determining the susceptibility to SB.